Marilita M Moschos1, Panagiotis Pantazis2, Zisis Gatzioufas3, Georgios D Panos4, Maria Gazouli5, Eirini Nitoda6, Dimitris Brouzas7. 1. University Eye Clinic, General Hospital of Athens G. Gennimatas, Greece. Electronic address: moschosmarilita@yahoo.fr. 2. University Eye Clinic, General Hospital of Athens G. Gennimatas, Greece. Electronic address: pantazispanos@hotmail.com. 3. Moorfields Eye Hospital, London, UK. Electronic address: zisisg@hotmail.com. 4. Ipswich Hospital, University of Cambridge, UK. Electronic address: gdpanos@gmail.com. 5. Department of Basic Medical Science, Laboratory of Biology, Medical School, National & Kapodistrian University of Athens, Greece. Electronic address: mgazouli@med.uoa.gr. 6. University Eye Clinic, General Hospital of Athens G. Gennimatas, Greece. Electronic address: irenenitoda@yahoo.com. 7. University Eye Clinic, General Hospital of Athens G. Gennimatas, Greece. Electronic address: brouzas@yahoo.com.
Abstract
AIM: To assess the role of plasma platelet activating factor acetylhydrolase (PAF-AH) in pathogenesis and progression of diabetic retinopathy (DR). MATERIALS AND METHODS: Sixty eight diabetics and 23 age-frequency-matched non-diabetic patients underwent blood sampling and the plasma PAF-AH activity was calculated. The diabetic patients were further classified into two groups, according to the Early Treatment Diabetic Retinopathy Study (ETDRS) classification, based on indirect fundoscopy and fluorescein angiography. Thirty seven patients with non-proliferative DR (NPDR) and 31 patients with proliferative DR (PDR) were finally included in the study. RESULTS: The plasma PAF-AH activity was increased in diabetic patients with PDR (0.206 μmol/min/ml) compared to control group (0.114 μmol/min/ml, post-hoc Bonferroni comparison test: p<0.0001) and to NPDR group (0.147 μmol/min/ml, post-hoc Bonferroni comparison test: p=0.012). CONCLUSIONS: The activity of PAF-AH in the plasma increases in parallel with DR severity.
AIM: To assess the role of plasma platelet activating factor acetylhydrolase (PAF-AH) in pathogenesis and progression of diabetic retinopathy (DR). MATERIALS AND METHODS: Sixty eight diabetics and 23 age-frequency-matched non-diabeticpatients underwent blood sampling and the plasma PAF-AH activity was calculated. The diabeticpatients were further classified into two groups, according to the Early Treatment Diabetic Retinopathy Study (ETDRS) classification, based on indirect fundoscopy and fluorescein angiography. Thirty seven patients with non-proliferative DR (NPDR) and 31 patients with proliferative DR (PDR) were finally included in the study. RESULTS: The plasma PAF-AH activity was increased in diabeticpatients with PDR (0.206 μmol/min/ml) compared to control group (0.114 μmol/min/ml, post-hoc Bonferroni comparison test: p<0.0001) and to NPDR group (0.147 μmol/min/ml, post-hoc Bonferroni comparison test: p=0.012). CONCLUSIONS: The activity of PAF-AH in the plasma increases in parallel with DR severity.